key: cord-0901274-aef1g81a
authors: Bertin, Daniel; Brodovitch, Alexandre; Beziane, Abdou; Hug, Sylvia; Bouamri, Afaf; Mege, Jean Louis; Bardin, Nathalie
title: Anti‐cardiolipin IgG autoantibodies are an independent risk factor of COVID‐19 severity
date: 2020-06-21
journal: Arthritis Rheumatol
DOI: 10.1002/art.41409
sha: 31a0f849105a018e3329cd1661b66f5635888f3d
doc_id: 901274
cord_uid: aef1g81a

A growing body of evidence indicates that patients with cardiovascular complications are at a higher risk for developing severe Coronavirus Disease 2019 (COVID‐19) (1). In addition, the high incidence of thromboembolic events suggests an important role of COVID‐19‐induced coagulopathy (2). Antiphospholipid autoantibodies (aPL), that are essential markers for antiphospholipid syndrome, are considered as a cardiovascular risk factor.

This article is protected by copyright. All rights reserved To Editor, A growing body of evidence indicates that patients with cardiovascular complications are at a higher risk for developing severe Coronavirus Disease 2019 (COVID-19) (1) . In addition, the high incidence of thromboembolic events suggests an important role of COVID-19-induced coagulopathy (2) . Antiphospholipid autoantibodies (aPL), that are essential markers for antiphospholipid syndrome, are considered as a cardiovascular risk factor. Their presence has been recently described in three patient presenting severe forms of COVID-19 (3), raising the question of their interest in COVID-19 severity management, a major problem expected in the pandemic management being the decision to keep newly infected patients in the hospital.

To this end, anti-cardiolipin (aCL) and anti-β2-glycoprotein I (aB2GPI) autoantibodies, IgG and IgM, were measured in serum samples from 56 COVID-19 cases with positive SARS-CoV-2 RT-PCR. According to clinical presentation at sampling time, this cohort was divided into two groups: a moderate (n= 27) and a severe group of patients (n=29). Disease severity was defined as described (4): respiratory rate >30/min, oxygen saturation ≤93%, PaO2/FiO2≤ 300 mmHg, shock or respiratory failure requiring the admission to an intensive care unit. All samples were part of a declared Biobank (DC 2020-4028) in compliance with ethical directives. aCL and aB2GPI antibodies were respectively determined by ELISA kits. Association between disease severity and clinico-biological features was analyzed by univariate and multivariate logistic regression (glm function; R software v4.0).

A summary of our results is provided in Table 1 . Additional information regarding material and methods and aPL levels results are available in supplemental data. No difference in term of age, gender, duration of symptoms, history of thrombosis, history of stroke, cardiovascular disorders, diabetes, and chronic respiratory disease was observed between the two groups of patients.

Difference in aPL profile was only found for aCL IgG that were significantly associated with severe form of the disease in a univariate (OR=6.50; p=0.009) confirmed by a multivariate analysis (OR=8.71; p=0.017), showing for the first time that aCL IgG is highly and independently associated with disease severity. Except for one patient presenting a stroke history, no other severe COVID-19 patient positive for aCL IgG presented a history of thrombosis, suggesting that aCL positivity could be attributed to severe SARS-CoV-2 infection. Indeed, viral infections are known

This article is protected by copyright. All rights reserved to induce aPL, especially aCL that may increase the thrombotic risk and clot formation in the presence of another thrombophilic condition (5) . Since patients with COVID-19 have a profound hypercoagulable state (6), aCL IgG positive patients are at a higher risk to develop thrombosis so their clinical and biological follow-up should be recommended. Common thromboembolic events are confirmed by recent autopsy data on patients who died from COVID-19 and may be unsuspected at the time of death, showing that almost half of venous thromboembolic events are not being recognized prior to death (2) , suggesting that some patients may need anticoagulation.

While awaiting further investigations, aCL detection could represent a simple strategy to help stratify patients with COVID-19 and to manage the therapeutic decision.

This article is protected by copyright. All rights reserved 

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan

Advances in the Research on Anticardiolipin Antibody

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19